About Tonix Pharma
Tonix Pharma is a publicly listed company based in New York (United States) founded in 2007. Next-generation medicines for CNS and immunological disorders are developed. Tonix Pharma has raised $4.45 million across 10 funding rounds from investors including NIH and Technology Partners. The company has 81 employees. Its website tonixpharma.com draws about 17 thousand monthly visits. Tonix Pharma offers products and services including TNX-102 SL, TNX-1300, TNX-1500, TNX-801, and TNX-1800. Its focus areas include Life Sciences, Neurology, Drugs and Neural Injury. Its legal entity is Tonix Pharmaceuticals Holding Corp. Its competitors include CareDx, PanTher Therapeutics and BioAge Labs; 3 of its 3 listed competitors have raised funding.
Company details
Tonix Pharma was founded in 2007 and is headquartered in New York, United States. Medicines targeting central nervous system and immunological disorders are developed by the company within the pharmaceutical sector. Operations focus on advancing therapeutic candidates, including TNX-601 (tianeptine oxalate) for post-traumatic stress disorder treatment and TNX-801 involving horsepox virus. Research and development activities are conducted to address unmet medical needs in these areas.
- Headquarters New York, United States
- Employees 81
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website tonixpharma.com
- Social LinkedIn X Facebook
- Legal Name Tonix Pharmaceuticals Holding Corp.
- Annual Revenue$13.11 M (USD)29.85as on Dec 31, 2025
- Net Profit-$124.02 M (USD)4.63as on Dec 31, 2025
- EBITDA-$123.78 M (USD)-66.54as on Dec 31, 2025
- Total Equity Funding$4.45M (USD)
in 10 rounds
- Latest Funding Round$15M (USD), Post-IPO
Oct 2022
- InvestorsNIH
& 1 more
- Employee Count81
Products & Services of Tonix Pharma
Tonix Pharma offers a comprehensive portfolio of products and services, including TNX-102 SL, TNX-1300, TNX-1500, TNX-801, and TNX-1800.
Drug for fibromyalgia and related disorders.
Therapy for cocaine intoxication and overdose.
Antibody for organ transplant rejection.
Vaccine candidate for mpox and smallpox.
Vaccine for COVID-19 and related viruses.
Treatment for Prader-Willi syndrome.
Funding Insights of Tonix Pharma
Tonix Pharma has successfully raised a total of $4.45M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.45M
- Total Rounds 10
- Last Round Post-IPO — $15M
- First Round $150,001
(Aug 2010)
- Investors Count 2
All 10 funding rounds of Tonix Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | $15M | Post-IPO | – | – | – |
| Aug 2022 | Grant | – | – | ||
| Jun 2022 | $30M | Post-IPO | – | – | – |
| Jul 2020 | $10.5M | Post-IPO | – | – | – |
| Oct 2017 | $314,798 | Post-IPO | – | – | – |
| Dec 2012 | $3.4M | Post-IPO | – | – | |
| Nov 2012 | $710,000 | Debt – Conventional | – | – | – |
| Jan 2012 | $4.3M | Series A | – | – | – |
| Oct 2011 | $1.63M | Debt – Conventional | – | – | – |
| Aug 2010 | $150,001 | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Tonix Pharma
Tonix Pharma has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH and Technology Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in US life sciences and energy companies. | technologypartners.com | Palo Alto, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Tonix Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tonix Pharma
30 people are tracked at Tonix Pharma (12 in leadership, 7 in board & advisors, 11 in team); the tracked headcount is 81.
| Name | Role | Group |
|---|---|---|
Betsy Nunez | Director, Human Resources | Leadership |
Gregory Sullivan | Chief Medical Officer | Leadership |
Seth Lederman | Co-Founder, CEO & Chairman | Leadership |
Jessica Edgar Morris | COO | Leadership |
Bradley Saenger | CFO | Leadership |
Lisa M. | Executive Assistant To Chief Medical Officer | Leadership |
Barbara Doupal | Associate Director, Accounts Payable | Leadership |
Robert Uff | Head Of Talent Acquisition | Leadership |
Benjamin Randolph | Director Of Information Technology | Leadership |
Debbie Gohegan | Director, Facility Operations | Leadership |
Amy Forst | Clinical Program Director | Leadership |
David Hsu | Senior Director, Clinical Science | Leadership |
Adeoye Olukotun | Director | Board & advisors |
Margaret Smith Bell | Director | Board & advisors |
David Grange | Director | Board & advisors |
James Treco | Director | Board & advisors |
Carolyn E. Taylor | Director | Board & advisors |
Richard H. Bagger | Director | Board & advisors |
R. Newcomb Stillwell | Director | Board & advisors |
Megha Shah Tevar | Sr. Manager, Clinical Programs | Team |
10 more people are available in the full profile.
Complete people profiles for Tonix Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Tonix Pharma
Tonix Pharma is a publicly listed company on the NASDAQ with ticker symbol TNXP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Nov 2012
- Listed onNASDAQ: TNXP
- Listed entityTonix Pharmaceuticals Holding Corp.
- Exchange sectorHealth technology
- ISINUS8902608392
- Share price$6.13 (-7.68% on the day) · 2026-10-13
- Market capitalisation$105.1M
- EPS (diluted, trailing year)$-12.93
- Volume (last session)1,138,605
Financials of Tonix Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $13.1M | -$124.0M | -$123.8M |
| 2024 | $10.1M | -$130.0M | -$74.3M |
| 2023 | $7.8M | -$116.7M | -$114.1M |
| 2022 | -$110.2M | -$110.8M | |
| 2021 | -$92.3M | -$92.3M |
Detailed financial statements for Tonix Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Tonix Pharma
4 dated milestones of Tonix Pharma across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Tonix Pharma is founded.
- Funding First funding round of $150K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $15.0M.
Competitors of Tonix Pharma
Tonix Pharma has 3 listed competitors in our database, 3 of them funded. They include CareDx, PanTher Therapeutics and BioAge Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| caredx.com | 1998 | Brisbane, United States | $138.21M | 645 | Medical solutions for transplant patients are developed and provided. | |
| panthertx.com | 2014 | Cambridge, United States | $15.35M | 47 | Drug delivery systems for inoperable solid tumors are developed. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. |
Detailed competitors of Tonix Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Tonix Pharma
The website of Tonix Pharma (tonixpharma.com) receives about 16.8K visits a month and ranks #1,258,659 among all websites worldwide, #1,596 in Biotechnology and Pharmaceuticals.
- Monthly visits16.8K
▼ 21.6% vs previous month
- Unique visitors9.8K
per month
- Global rank#1,258,659
among all websites
- Category rank#1,596
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.9
- Average visit25 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Tonix Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mereobiopharma.com | 100% | 17K | #2,596,874 | View details | |
| telixpharma.com | 98% | 31.7K | #937,266 | View details | |
| x-chemrx.com | 95% | 3.7K | #5,330,424 | View details | |
| crinetics.com | 95% | 21.7K | #1,355,406 | View details | |
invest.arenapharm.com | invest.arenapharm.com | 93% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Tonix Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Tonix Pharma (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tonix Pharma
Complete news archive for Tonix Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tonix Pharma
Tonix Pharma was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Tonix Pharma is headquartered in New York, United States. It is registered at New York, New York, United States.
Tonix Pharma is a funded company, having raised a total of $4.45M across 10 funding rounds to date. The company's 1st funding round was a Seed of $150K, raised on Aug 2010.
Tonix Pharma has 81 employees.
Annual revenue of Tonix Pharma is $13.11M as on Dec 31, 2025.
Tonix Pharma was founded in 2007 and is headquartered in New York, United States. Medicines targeting central nervous system and immunological disorders are developed by the company within the pharmaceutical sector. Operations focus on advancing therapeutic candidates, including TNX-601 (tianeptine oxalate) for post-traumatic stress disorder treatment and TNX-801 involving horsepox virus. Research and development activities are conducted to address unmet medical needs in these areas.
Tonix Pharma's top competitors include CareDx, PanTher Therapeutics and BioAge Labs.
Tonix Pharma offers TNX-102 SL, TNX-1300, TNX-1500, TNX-801, and 2 more products and services.
Yes, Tonix Pharma is publicly traded on NASDAQ under the ticker symbol TNXP.
Tonix Pharma has 2 investors. Key investors include NIH, and Technology Partners.
Tonix Pharma operates through Tonix Pharmaceuticals Holding Corp.